DOUGLAS E WILLIAMS
CIK 1184847 · EVP & President, R&D · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.02M
Companies
11
Total Filings
78
Lifetime Open-Market Net
-$3.68M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $4.65 | — | $0 | 2 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 4 | 2026-06-08 |
| SANA | EVP & President, R&D | — | $4.10 | — | $0 | 3 | 2024-03-08 |
| Codiak BioSciences, Inc. (CDAK) Delisted | President & CEO | 7,655 | $0.06 | $436 | -$30.7K | 8 | 2023-03-30 |
| OVID | Director | 5,000 | $2.93 | $14.7K | $32.4K | 7 | 2021-05-18 |
| IRWD | Director | 87,800 | $4.36 | $382.8K | $0 | 5 | 2019-04-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | — | $8.16 | — | $0 | 4 | 2016-06-03 |
| BIIB | EVP Research & Development | 11,817 | $221.56 | $2.62M | -$3.73M | 16 | 2015-06-22 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 19,961 | — | — | $0 | 8 | 2013-06-14 |
| ZYMOGENETICS INC (ZGEN) Delisted | Chief Executive Officer | 0 | $12.01 | $0 | $47.0K | 12 | 2010-10-12 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 4,500 | — | — | $4.7K | 4 | 2008-05-30 |
Recent Filings · Page 5 of 8
78 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-08-28 | BIIB | Sell (S) | −4,368 | -$923.2K | EDGAR |
| 2013-06-14 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-06-11 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Tax (F) | −1,135 | -$2.1K | EDGAR |
| 2013-06-10 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-02-14 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2013-02-12 | BIIB | Mixed | +1,754 | -$205.9K | EDGAR |
| 2013-02-05 | BIIB | Mixed | +3,480 | -$264.1K | EDGAR |
| 2012-11-08 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-08 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Grant (A) | +8,174 | $30.0K | EDGAR |
| 2012-06-05 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Mixed | −4,341 | -$7.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.